Pamela Soliman, MD
Gynecologic Oncology · Houston, TXNPI 1740367887
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $31,019 of the $37,311 with a category attached, or 83.1%. 11 manufacturers reported payments, led by GSK at 36.2% of the total. Reporting peaked in 2023 at $11,269 and has fallen 59.5% since, to $4,568 in 2025.
Across 48 payments — averaging $777.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$13K
- Tesaro, Inc.$7K
- Eisai Inc.$6K
- Aadi Bioscience, Inc.$6K
- Amgen$3K
- AbbVie$485
- plus $1K from 5 others
Across 27 payments — averaging $1,134,960 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$29.3M
- Merck$674K
- GSK$574K
- Incyte Corporation$69K
What the payments were for
- Consulting fees$31,01983%
- Speaking & faculty fees$2,4607%
- Travel & lodging$1,3124%
- Food & beverage$2,5207%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 7 | $13,496 |
| Tesaro, Inc. | 9 | $7,482 |
| Eisai Inc. | 5 | $6,174 |
| Aadi Bioscience, Inc. | 8 | $6,017 |
| Amgen | 2 | $2,596 |
| AbbVie | 6 | $485 |
| Clovis Oncology, Inc. | 4 | $344 |
| Intuitive Surgical | 2 | $241 |
| Johnson & Johnson | 3 | $184 |
| Stryker | 1 | $167 |
| Genentech USA, Inc. | 1 | $127 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$37,311 in reported general payments places this provider in the 85th percentile of 135 gynecologic oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LynparzaOlaparib | 13 | $132,710 |
| EliquisApixaban | 20 | $11,385 |
| Megestrol Acetate | 32 | $923 |
| Tamoxifen Citrate | 23 | $893 |
| Letrozole | 23 | $349 |
| Ondansetron Hcl | 22 | $113 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Houston
- Robert ColemanHouston$864K
- Maurie MarkmanHouston$204K
- Michael FrumovitzHouston$156K
- Aparna KamatHouston$116K
- Anuj SuriHouston$72K
- Anil SoodHouston$69K
- Pedro RamirezHouston$42K
- Anthony CostalesHouston$17K
- Travis SimsHouston$14K
- Lois RamondettaHouston$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.